Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT04740905) enrolled 553 people in total — 276 in one group (Arm A) and 277 in the other (Arm B). The trial was testing two eye injection treatments, faricimab and aflibercept, in people with a condition affecting their vision. The study ran in two parts: the first 24 weeks (Part 1) compared the two treatments given every four weeks, and a second phase ran through to week 72. The main thing the trial was measuring was how much participants' vision changed from the start of the trial to week 24, using a standard eye chart test (where a higher score means better vision). The reported data shows that, at week 24, participants in the faricimab group gained an average of 16.9 letters on the eye chart from their starting score, while those in the aflibercept group gained an average of 17.5 letters. For context on how many people saw larger gains: around 56% of people in the faricimab group and around 60% in the aflibercept group gained 15 or more letters by week 24. When looking at a smaller gain of 10 or more letters, the reported figures were approximately 78% for the faricimab group and 77% for the aflibercept group at week 24. For a gain of 5 or more letters, the reported figures were approximately 91% and 90% respectively. The reported data also shows that vision scores improved across both groups at every check-in point throughout the 24 weeks, with gains building gradually from the earliest visits. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 38280653) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Retinal Vein Occlusion and Diabetic Macular Oedema Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have swelling in the central part of your retina (the back of your eye) caused by a blocked vein in the eye, and this was diagnosed no more than 4 months ago
- Your vision in the affected eye falls within a specific range — roughly between 20/40 and 20/400 on a standard eye chart
- The inside of your eye is clear enough, and your pupil can dilate enough, to allow good-quality photographs of your retina to be taken
- If you are a woman who could become pregnant, you agree to use contraception or remain abstinent, and to avoid donating eggs, during the treatment and for 3 months after your last dose
Who may not be able to join:
- You had a serious illness or major surgery within 1 month before your screening appointment
- Your blood pressure is not well controlled
- You had a stroke or heart attack within the 6 months before the study starts
- You are currently pregnant, breastfeeding, or planning to become pregnant during the study
- You have had previous episodes of retinal swelling from a blocked vein in the eye, or your current swelling was first diagnosed more than 4 months ago
- You have another eye condition (besides the blocked vein) that the doctors believe is causing or could cause permanent vision loss in the affected eye (confirm with trial site)
- You have ever had a specific type of eye laser treatment called macular laser in the affected eye
- You have had a full eye laser treatment (panretinal photocoagulation) in the affected eye within the past 3 months, or one is planned within 3 months of the study starting
- You have had any previous treatment for retinal swelling or related eye conditions, including injections into the eye, certain eye surgeries, or steroid treatments (confirm with trial site for full list)
- You have ever had a specific light-based eye treatment (photodynamic therapy), heat-based laser treatment, or surgery on the jelly inside your eye (vitreo-retinal surgery)
- You have ever had a steroid implant placed inside your eye (such as Ozurdex or Iluvien)
- You have previously received an injection of a specific drug called faricimab in either eye
- You have a history of inflammation inside either eye caused by the immune system or an unknown cause
- You currently have any active inflammation or infection in or around either eye
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Clinical Trials, Hoffmann-La Roche
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
6 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Part 1: Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye at Week 24
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.